Positive Phase IIIb data for Novo Nordisk’s once-weekly IcoSema

Danish diabetes care giant Novo Nordisk (NOV: N) has release top-line results from the COMBINE 3 Phase IIIa trial of once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide.

COMBINE 3 was a 52-week, open-label treat-to-target trial comparing the efficacy and safety of once-weekly IcoSema versus once-daily insulin glargine U100 and insulin aspart (injected 2-4 times a day during mealtimes), dosed with or without oral glucose-lowering medications, in 679 people with type 2 diabetes (T2D) inadequately controlled on daily basal insulin.

The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with once-weekly IcoSema compared with insulin glargine U100 and insulin aspart.